AS Brett
Abstract
Sumatriptan came into clinical use for migraine primarily based on the strength of placebo-controlled trials rather than comparisons with other agents.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Sumatriptan came into clinical use for migraine primarily based on the strength of placebo-controlled trials rather than comparisons with other agents.
Key concepts: Dihydroergotamine, Sumatriptan, Migraine, Medicine, Anesthesia, Migraine Disorders, Internal medicine, Receptor